Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Says AbbVie Returns Rights for CD47, Ending $2 Billion Partnership

publication date: Sep 25, 2023

Shanghai’s I-Mab announced AbbVie will end its CD47 partnership with I-Mab, returning all rights for the drug. In 2020, AbbVie acquired ex-China rights to the drug in a deal worth up to $2 billion, including options on two other I-Mab candidates. I-Mab will keep $200 million in AbbVie upfront and milestone payments. AbbVie said the breakup was a “strategic decision,” a description that wasn’t explained, though the company has ended several partnerships recently. One year ago, AbbVie reduced the scope of the I-Med partnership, stopping two Phase Ib trials of lemzoparlimab. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital